Myeloid-derived immunosuppression of chimeric antigen receptor T cells in the neuronal microenvironment of glioblastoma

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Chimeric antigen receptor (CAR)-T cell therapy remains largely ineffective in glioblastoma (GB), where a highly immunosuppressive microenvironment and tumor heterogeneity impair therapeutic durability.

Methods

Using a human neocortical brain slice model that preserves the complex GB microenvironment, we profiled interactions between natural killer group 2D ( NKG2D ) CAR-T cells and tumor ecosystems via PIC-seq, spatial transcriptomics, and gene regulatory network reconstruction.

Results

CAR-T cells showed an early but unsustained tumor-suppressive effect in the slice model. Single-cell profiling revealed that CAR CD8 T cells adopt an effector-skewed activation state accompanied by coordinated upregulation of checkpoint receptors and an exhaustion-associated transcription factor program. These transcriptional changes were linked to ligand-receptor signaling interactions between CAR-T cells and myeloid populations. Tumor-associated macrophages displayed enhanced phagocytic programs and spatially co-localized with mesenchymal-like GB cells within hypoxic regions. Gene regulatory network analysis identified MAF and BACH2 as candidate regulators of CD8 T cell state, with MAF enriched in CAR CD8 T cells exhibiting exhaustion-like features, and BACH2 enriched in Mock CD8 T cells consistent with less differentiated programs. In silico perturbation analyses further suggested a reciprocal effect of MAF and BACH2 on CD8 T cell transcriptional trajectories.

Conclusions

These data map the microenvironmental and transcriptional changes associated with rapid CAR-T cell dysfunction in GB and identify candidate pathways and regulators that may be leveraged to engineer more durable cellular therapies.

Article activity feed